Cresco acted as lead counsel to Novalis and Qbic on their Series A investment in Trince.
Trince, a spin-off of Ghent University (UGent), is developing innovative and efficient technology to insert genetic material into cells. This genetic modification of cells is essential in, for example, cell therapy – an anti-cancer treatment that has become an integral part of modern medicine.
Trince has raised EUR 4 million from Novalis Biotech Acceleration, Qbic II, and private investors.
Olivier van Raemdonck led the Cresco team that advised the investors in this transaction.
More information on this transaction can be found in De Tijd.
For any further information or questions, please contact Olivier van Raemdonck.